Traitements de palier 5 dans l’asthme
- 1 June 2020
- journal article
- Published by Elsevier BV in Revue des Maladies Respiratoires Actualités
- Vol. 12 (1), S11-S14
- https://doi.org/10.1016/s1877-1203(20)30004-5
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Tezepelumab in Adults with Uncontrolled AsthmaThe New England Journal of Medicine, 2017
- Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in FranceBMJ Open, 2017
- Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trialThe Lancet, 2017
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaThe New England Journal of Medicine, 2017
- Burden of systemic glucocorticoid-related complications in severe asthmaCurrent Medical Research and Opinion, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004